Daily Brief India: National Stock Exchange, RBL Bank, Supriya Lifescience, HDFC Bank (ADR), Bajaj Finserv , Aptus Pharma, Adroit Infotech and more

• National Stock Exchange (NSEIN IN) raised about US$2.4bn in its India IPO.
• NSE operates electronic platforms for trading equities, derivatives, currencies, and debt securities, also earning revenue from clearing and settlement services, market data, index licensing, listing fees, connectivity, and technology services.
• We have looked at the company’s past performance and valuations in our previous note. In this note, we will talk about the trading dynamics.

• Emirates NBD’s landmark ₹26,016 crore (USD 2.75 billion) primary capital infusion on June 18, 2026, for a 60% controlling stake has fundamentally reset RBL Bank’s balance sheet, pushing its Capital Adequacy Ratio (CRAR) to 33.28% and eliminating any equity dilution or capital-raising risks for the next 3 to 5 years.
• Structural profitability remains a critical challenge, with Return on Assets (ROA) sitting at a subdued 0.57% in Q1 FY27. Net Interest Margin (NIM) compressed significantly to 4.13%, dragged down by the immediate liquidity-deployment friction of the new capital and a tactical pivot towards lower-yielding wholesale advances (which grew 38% YoY to ₹52,027 crore) to manage overall credit risk.
• The retail book’s seasoned vintages from mid-2024 to early 2025 represent the core credit vulnerability. Co-branded credit cards and digital personal loans sourced via fintech partnerships during the peak of the aggressive expansion phase have seen early-bucket (30-90 DPD) delinquencies trend 120 to 150 basis points above pre-COVID norms, driving elevated credit card slippages of ₹7.4 billion in Q1 FY27 and prompting a severe pruning of digital-partner originations.

• Market Leadership & Backward Integration Advantage: Supriya Lifescience Limited (SUPRIYA IN) is a niche active pharmaceutical ingredient (API) and finished dosage formulation (FDF) manufacturer with global leadership in key molecules across antihistamines, anesthetics, vitamins, and anti-asthmatics. Over 75% of its API portfolio is backward integrated to the basic starting material stage, delivering industry-leading EBITDA margins (35-38%) and shielding operations from raw material price volatility.
• Strong High-Margin Growth Trajectory: The company demonstrated strong financial performance with revenue expanding at a 3-year CAGR of 21.23% to reach INR 8,278.75M in FY26, alongside a 32.52% net income CAGR to INR 2,091.20M. Growth is supported by deepening penetration across regulated export markets (Europe, North America, LATAM), long-term strategic contracts (e.g., DSM-Firmenich for Vitamin B2), and an expanding finished formulation pipeline.
• Strategic Expansion into Formulations and CDMO: Commercialization of the Ambernath FDF and CDMO facility alongside capacity additions at the Lote Parshuram site (Module E taking reactor capacity to 1,020 KLPD) and upcoming Patalganga greenfield site establishes a clear roadmap toward management’s INR 16,000M medium-term revenue aspiration. Balance sheet strength remains pristine with net-cash positioning and self-funded growth.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Post-Merger Balance Sheet Normalization: HDFC Bank (ADR: HDB US, $22.79) is executing a measured transition strategy following its landmark merger with HDFC Ltd, actively re-aligning its Loan-to-Deposit Ratio (LDR) through accelerated retail deposit mobilization while moderating wholesale credit growth to safeguard Net Interest Margins (NIM).
• Resilient Earnings Power and Cash Flow Generation: The bank demonstrated robust fundamentals in FY26, generating $56.91B in revenue and $8.60B in net income with stable net margins of 15.12%, supported by a dramatic expansion in Operating Cash Flow to $18.97B and Free Cash Flow to $18.53B.
• Attractive Valuation Asymmetry: A persistent disconnect exists between HDFC Bank’s operational compounding (10-year Revenue and Net Income CAGRs of 17.48% and 15.97%) and recent equity performance (3-year Market Cap CAGR of -9.29%), creating an attractive entry point for institutional investors seeking premier exposure to Indian structural credit growth.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Context: The Bajaj Finserv (BJFIN IN) vs. Kotak Mahindra Bank (KMB IN) price ratio has deviated more than two standard deviations from its average, presenting a potential relative value opportunity.
• Highlight: Going long Bajaj Finserv (BJFIN IN) and short Kotak Mahindra Bank (KMB IN) targets a 4% return.
• Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.

• Aptus Pharma Ltd. (APPL IN) operates an asset-light pharmaceutical marketing and distribution model with over 210 finished formulations across 11+ therapeutic categories, delivering a robust two-year revenue CAGR of 61.5% to reach INR 465.72M in 2026.
• Despite strong reported accounting profitability (EBITDA margin of 16.0% and Net Margin of 9.9% in 2026), the company exhibits severe cash flow conversion deficits, with Operating Cash Flow deteriorating to -INR 62.68M and Free Cash Flow to -INR 84.54M due to heavy working capital absorption.
• At a last traded price of INR 347.05, the stock trades at elevated valuation multiples (~125x-130x trailing P/E) with a Smartscore Value rating of 2/5 and zero dividend yield, reflecting significant execution risk against third-party CMO dependencies, regional concentration, and high generic competitive intensity.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

• Specialized SAP ERP Integration Footprint: Adroit Infotech Limited is a Hyderabad-based niche IT consulting firm providing comprehensive SAP lifecycle services, including SAP S/4 HANA migrations, conventional ECC implementations, custom FIORI applications, and SAP BTP cloud integrations across domestic and global markets.
• Revenue Expansion Amid Margin Volatility: The company demonstrated strong top-line momentum, expanding revenue at a 3-year CAGR of 29.42% to reach INR 486.58M in FY2026, though operational profitability and gross margins have shown quarterly cyclicality due to project mobilization and delivery cycles.
• Strategic Repositioning via Verso Altima India: Adroit is accelerating growth through wholly-owned subsidiary Verso Altima India (VAI), leveraging SAP PartnerEdge – Sell authorization and newly appointed executive leadership (Group CEO and COO) to capture higher-margin enterprise cloud migrations and managed services.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.